Carmustine | |
系統(IUPAC)名字 | |
1,3bis (2chloroethyl) - 1亞硝基尿素 | |
標識符 | |
化工數據 | |
214.049 g/mol | |
約物動力學的數據 | |
5到28% (口頭) | |
80% | |
15 |
資料來源:http://en.wikipedia.org/wiki/Carmustine
N,N'-bis(2-chloroethyl)-N-nitroso-urea | |
154-93-8 | |
L01AD01 | |
CID 2578 | |
APRD00006 | |
2480 Y | |
U68WG3173Y Y | |
D00254 Y | |
CHEMBL513 Y | |
C5H9Cl2N3O2 | |
214.049 g/mol | |
eMolecules & PubChem | |
5 to 28% (oral) | |
80% | |
Hepatic (CYP1A2-mediated) | |
15 to 30 minutes | |
D(US) | |
℞ Prescription only | |
Intravenous, wafer for implant | |
Carmustine or BCNU (= "bis-chloronitrosourea") is a mustard gas-related α-chloro-nitrosourea compound used as an alkylating agent in chemotherapy.
Carmustine for injection is marketed under the name BiCNU by Bristol-Myers Squibb.
Uses
It is used in the treatment of several types of brain cancer (including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma), multiple myeloma and lymphoma (Hodgkin's and non-Hodgkin).
Side effects
Male infertility.
Bone marrow may take 6 weeks to recover function following treatment with carmustine. Weekly monitoring of platelet and white blood cell counts are recommended as a basis for patient-specific adjustments to dosage regimens. Bone marrow and pulmonary toxicities are a function of lifetime cumulative dose.
留言列表